Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology

Áron Bartha,Balázs Győrffy,Bartha,Győrffy

DOI: https://doi.org/10.3390/cancers11111725

2019-11-04

Cancers

Abstract:Whole exome sequencing (WES) enables the analysis of all protein coding sequences in the human genome. This technology enables the investigation of cancer-related genetic aberrations that are predominantly located in the exonic regions. WES delivers high-throughput results at a reasonable price. Here, we review analysis tools enabling utilization of WES data in clinical and research settings. Technically, WES initially allows the detection of single nucleotide variants (SNVs) and copy number variations (CNVs), and data obtained through these methods can be combined and further utilized. Variant calling algorithms for SNVs range from standalone tools to machine learning-based combined pipelines. Tools for CNV detection compare the number of reads aligned to a dedicated segment. Both SNVs and CNVs help to identify mutations resulting in pharmacologically druggable alterations. The identification of homologous recombination deficiency enables the use of PARP inhibitors. Determining microsatellite instability and tumor mutation burden helps to select patients eligible for immunotherapy. To pave the way for clinical applications, we have to recognize some limitations of WES, including its restricted ability to detect CNVs, low coverage compared to targeted sequencing, and the missing consensus regarding references and minimal application requirements. Recently, Galaxy became the leading platform in non-command line-based WES data processing. The maturation of next-generation sequencing is reinforced by Food and Drug Administration (FDA)-approved methods for cancer screening, detection, and follow-up. WES is on the verge of becoming an affordable and sufficiently evolved technology for everyday clinical use.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to comprehensively overview the data analysis tools of whole exome sequencing (WES) in clinical oncology and their applications. Specifically, the paper focuses on the following aspects: 1. **Technical Background**: It introduces how WES detects cancer - related genetic variations by analyzing all protein - coding sequences in the human genome. These variations are mainly located in exon regions. WES can provide high - throughput results at a reasonable cost, enabling researchers to simultaneously monitor multiple different genomic changes in tumor tissues. 2. **Data Processing Tools**: It reviews various tools for WES data analysis, including detection tools for single nucleotide variants (SNVs) and copy number variations (CNVs). These tools range from independent software to comprehensive pipelines based on machine learning, aiming to improve the accuracy and efficiency of variation detection. 3. **Clinical Applications**: It explores the potential clinical applications of WES, such as guiding the use of PARP inhibitors by identifying homologous recombination deficiency (HRD), and selecting patients suitable for immunotherapy by determining microsatellite instability (MSI) and tumor mutation burden (TMB). 4. **Technical Limitations**: It discusses some limitations of WES, including its limited ability to detect CNVs, lower coverage compared to targeted sequencing, and the lack of consensus on reference standards and minimum application requirements. 5. **Future Prospects**: It looks forward to the development trends of WES technology. In particular, with the maturity of next - generation sequencing technology and the application of FDA - approved cancer screening, detection, and follow - up methods, WES is gradually becoming an economical and efficient technology in daily clinical use. Overall, this paper aims to provide a comprehensive guide of tools and techniques for the utilization of WES data in clinical and research settings, promoting the application and development of WES in cancer research and clinical diagnosis.

Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology

Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape

Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities

Comparison of medical management and genetic counseling options pre- and post-whole exome sequencing for patients with positive and negative results.

EXaCT-2: An augmented and customizable oncology-focused whole exome sequencing platform

Advancing Personalized Medicine Through the Application of Whole Exome Sequencing and Big Data Analytics

On the Boundary of Exploratory Genomics and Translation in Sequential Glioblastoma

Whole genome sequencing in clinical practice

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Review of Current Methods, Applications, and Data Management for the Bioinformatics Analysis of Whole Exome Sequencing

Clinical application of whole-exome sequencing across clinical indications

Evaluation of Somatic Copy Number Estimation Tools for Whole-Exome Sequencing Data

An evaluation of copy number variation detection tools from whole-exome sequencing data.

Detection of Copy Number Variants and Loss of Heterozygosity from Impure Tumor Samples Using Whole Exome Sequencing Data.

Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage

Abstract 889: Machine learning-enhanced targeted versus whole-exome sequencing as a guide to cancer care

Clinical Interpretation and Implications of Whole-Genome Sequencing

The usefulness of whole-exome sequencing in routine clinical practice

A review of consensus statements, practice resources, standards and guidelines for clinical applications of next-generation sequencing technologies in the United States

Untargeted Profiling of Cell-Free Circulating DNA

Whole genome sequencing analysis for cancer genomics and precision medicine